Samuel Backenroth - 31 Mar 2023 Form 4 Insider Report for Vascular Biogenics Ltd.

Role: Chief Financial Officer
Signature: /s/ Samuel Backenroth
Issuer symbol: N/A
Transactions as of: 31 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Apr 2023, 16:36:39 UTC
Previous filing: 03 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VBLT	Ordinary Shares	Options Exercise		+525,000			525,000	31 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VBLT	Restricted Stock Units	Options Exercise	$0	-525,000	-75%	$0.000000	175,000	31 Mar 2023	Ordinary Shares	525,000		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the vesting and settlement of a portion of restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents a contingent right to receive one Ordinary Share, par value NIS 0.01, with an exercise price of NIS 0.01 per Ordinary Share.
F2	75% of the RSUs vested on March 31, 2023, with the remaining 25% vesting on August 9, 2024. The RSUs have no expiration date and have an exercise price of NIS 0.01 per Ordinary Share.